Loading…
Employees: 1,412
Size Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $716M, the 3014th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥43.73 on 6 Nov 2026.
Performance Over six months the shares fell 23.5%, against -6.4% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +16.1%); the operating margin is -29.9% (peer median 15.1%).
Valuation It trades at 64.3× forward earnings against a peer median of 15.2× (4th most expensive of 12).
Capital Return on invested capital runs 10.3 points below its cost of capital (8.8% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥618M | CN¥678M | CN¥802M | CN¥1.02B | CN¥607M |
| Revenue growth | — | -15% | -21% | +68% | — |
| Gross profit | CN¥260M | CN¥186M | CN¥330M | CN¥614M | CN¥381M |
| EBITDA | n/a | CN¥74.7M | CN¥101M | CN¥353M | CN¥197M |
| Net income | -CN¥178M | -CN¥90.4M | -CN¥52.7M | CN¥272M | CN¥194M |
| Free cash flow | -CN¥71.3M | -CN¥250M | -CN¥590M | -CN¥598M | -CN¥332M |
| Capital expenditure | CN¥85.8M | CN¥97.9M | CN¥395M | CN¥689M | CN¥592M |
| Total debt | CN¥950M | CN¥884M | CN¥724M | CN¥474M | CN¥36.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301096.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.3% | -10.1% | 9th highest of 21 |
| 6-month return | -23.5% | -6.4% | 5th lowest of 21 |
| Distance from 52-week high | -43.3% | -29.4% | 8th lowest of 21 |
| Revenue growth (TTM) | +4.7% | +16.1% | 6th lowest of 17 |
| Operating margin | -29.9% | 15.1% | 2nd lowest of 16 |
| Forward P/E | 64.3× | 15.2× | 4th most expensive of 12 |
| ROIC minus cost of capital | -10.3 pp | +0.5 pp | 3rd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 225.1× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 3.3× | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 11.9× | -1.1% | +22.1% |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 123.9× | 33.8% | +19.8% |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |